BioNTech and Pfizer's COVID19 vaccine shows potential in human trial
FRANKFURT - A COVID-19 vaccine developed by German biotech firm BioNTech and US pharmaceutical giant Pfizer has shown potential and was found to be well tolerated in early-stage human trials, the companies said Wednesday.
BioNTech's shares were up 4.6 percent, after rising as much as 19 percent to reach their highest in more than 3 months. It said the higher of the 2 doses - both administered via 2 injections within 3 weeks of one another - was followed by a short fever in 3 out of 4 participants after the second shot.
He said larger trials were being prepared to show whether this translates into protection against a real infection. Early-stage human trials of vaccines are designed to measure certain antibodies and other immune markers in the blood as an indicator of the body's readiness to fight an infection that then requires further validation.
If it eventually gets marketing approval, the companies are gearing up to make up to 100 million doses by the end of 2020 and another 1.2 billion doses by the end of 2021 at sites in Germany and the United States.The manuscript with the preliminary data from the clinical trials, which were launched in April and May, is under peer review for publication in a scientific journal, BioNTech said.
Philippines Latest News, Philippines Headlines
Similar News:You can also read news stories similar to this one that we have collected from other news sources.
BioNTech, Pfizer report progress in coronavirus vaccine trialKnown as BNT162b1, it produces antibody responses at or above the levels seen in any convalescent serum – blood from people who have recovered – at relatively low doses.
Read more »
India's first COVID-19 vaccine candidate approved for human trials
Read more »
PH COVID-19 cases may hit a staggering 60,000 by end of July—expertsMANILA, Philippines — Despite the government’s claim that the country is “winning” the fight against COVID-19, experts projections showed that coronavirus infections in the Philippines may
Read more »
BioNTech, Pfizer report progress in coronavirus vaccine trialKnown as BNT162b1, it produces antibody responses at or above the levels seen in any convalescent serum – blood from people who have recovered – at relatively low doses.
Read more »
Fujifilm ties up with Indian firm on potential COVID-19 drug Avigan
Read more »